KR20120107962A - 고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물 - Google Patents

고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20120107962A
KR20120107962A KR1020127015545A KR20127015545A KR20120107962A KR 20120107962 A KR20120107962 A KR 20120107962A KR 1020127015545 A KR1020127015545 A KR 1020127015545A KR 20127015545 A KR20127015545 A KR 20127015545A KR 20120107962 A KR20120107962 A KR 20120107962A
Authority
KR
South Korea
Prior art keywords
alkyl
halo
substituted
alkoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127015545A
Other languages
English (en)
Korean (ko)
Inventor
실비아 부오나미치
마리온 도르쉬
까를로스 가르시아-에체베리아
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120107962(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20120107962A publication Critical patent/KR20120107962A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127015545A 2009-11-18 2010-11-17 고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물 Withdrawn KR20120107962A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26234209P 2009-11-18 2009-11-18
US61/262,342 2009-11-18
US29203210P 2010-01-04 2010-01-04
US61/292,032 2010-01-04

Publications (1)

Publication Number Publication Date
KR20120107962A true KR20120107962A (ko) 2012-10-04

Family

ID=43384585

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127015545A Withdrawn KR20120107962A (ko) 2009-11-18 2010-11-17 고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물

Country Status (18)

Country Link
US (2) US20120232087A1 (enExample)
EP (1) EP2501370A1 (enExample)
JP (1) JP2013511526A (enExample)
KR (1) KR20120107962A (enExample)
CN (2) CN102665700A (enExample)
AU (1) AU2010322114B2 (enExample)
BR (1) BR112012011823A2 (enExample)
CA (1) CA2781210A1 (enExample)
CL (1) CL2012001271A1 (enExample)
IL (1) IL219636A0 (enExample)
MA (1) MA33739B1 (enExample)
MX (1) MX2012005695A (enExample)
NZ (1) NZ599964A (enExample)
PH (1) PH12012500911A1 (enExample)
RU (1) RU2012125152A (enExample)
TN (1) TN2012000205A1 (enExample)
WO (1) WO2011062939A1 (enExample)
ZA (1) ZA201203325B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
SG194800A1 (en) * 2011-06-02 2013-12-30 Novartis Ag Biomarkers for hedgehog inhibitor therapy
US9655909B2 (en) 2012-01-12 2017-05-23 Board Of Regents, The University Of Texas System Personalized medicine for the prediction of therapy targeting the hedgehog pathway
ES2664782T3 (es) * 2012-11-05 2018-04-23 Nantbio, Inc Derivados que contienen sulfonamida cíclica como inhibidores de la ruta de señalización de hedgehog
CN103524535B (zh) * 2013-10-16 2016-07-13 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
LT3786160T (lt) 2017-10-27 2022-09-26 Boehringer Ingelheim International Gmbh Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2020061584A1 (en) * 2018-09-21 2020-03-26 Msb Holdings, Inc. Taste-masked dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
CA2628920C (en) 2005-11-22 2015-12-29 Kudos Pharmaceuticals Limited Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
AU2007287430B2 (en) 2006-08-23 2011-07-21 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
MX2009013273A (es) * 2007-06-07 2010-01-25 Irm Llc Derivados de bifenil-carboxamida como moduladores de la senda de hedgehog.
ES2505091T3 (es) * 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
EP2249844A1 (en) * 2008-03-12 2010-11-17 Ludwig-Maximilians-Universität München Active substance combination with gemcitabine for the treatment of epithelial cancer
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Also Published As

Publication number Publication date
CA2781210A1 (en) 2011-05-26
ZA201203325B (en) 2013-01-30
IL219636A0 (en) 2012-07-31
US20150025074A1 (en) 2015-01-22
TN2012000205A1 (en) 2013-12-12
EP2501370A1 (en) 2012-09-26
AU2010322114A1 (en) 2012-05-31
CL2012001271A1 (es) 2012-10-12
PH12012500911A1 (en) 2012-11-26
NZ599964A (en) 2014-08-29
RU2012125152A (ru) 2013-12-27
MX2012005695A (es) 2012-06-13
JP2013511526A (ja) 2013-04-04
BR112012011823A2 (pt) 2019-09-24
AU2010322114B2 (en) 2014-07-31
CN104224791A (zh) 2014-12-24
CN102665700A (zh) 2012-09-12
US20120232087A1 (en) 2012-09-13
MA33739B1 (fr) 2012-11-01
WO2011062939A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
KR20120107962A (ko) 고형 종양 및 다른 악성종양의 치료를 위한 방법 및 조성물
TWI827646B (zh) Ptpn11抑制劑
AU2009299927B2 (en) Smoothened antagonism for the treatment of hedgehog pathway-related disorders
ES2789331T3 (es) Inhibidores de TGF-beta
KR101217316B1 (ko) 헷지호그 경로 조절제로서의 바이페닐카르복스아미드 유도체
RU2521394C2 (ru) Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток
CN102143958B (zh) 作为smo抑制剂的哒嗪衍生物
CN105899493A (zh) 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
CN116234797A (zh) 用于治疗癌症的tead的杂环抑制剂
JP2018534243A (ja) アンドロゲン受容体拮抗薬
US20150209365A1 (en) Methods and Compositions for Treating Luekemia
CN120712263A (zh) 瞬时受体电位香草素6抑制剂
HK1183625A (en) Smoothened antagonism for the treatment of hedgehog pathway-related disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120615

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid